Monday, April 2, 2007

Patmos Global Limited Acquires Gice Life Sciences Limited Shares For Gbp 5 Million Sterling

Patmos Global Limited Acquires Gice Life Sciences Limited Shares For Gbp 5 Million Sterling

The Board of Directors and trustees of PATMOS Global Limited today announced the acquisition of GICE Life Sciences Limited shares for GBP Sterling 5 million in cash and 10 percent collateralised securities provided by Lords of the Land Pty. Ltd. for a 30% stake.

Brisbane, Australia (PRWEB) October 27, 2006

The Board of Directors and trustees of PATMOS Global Limited today announced the acquisition of GICE Life Sciences Limited shares for GBP Sterling 5 million in cash and 10 percent collateralised securities provided by Lords of the Land Pty. Ltd. for a 30% stake. The President of GICE Security Ltd, Dr. Leonard Fernando today announced that the acquisition of shares by PATMOS Global Limited opens a new era in the Company's strategic partnership with Lords of the Land Pty Ltd. in fulfilling the commercial obligations as a PATMOS Covenant Partner.

With this acquisition of shares in GICE Life Sciences Limited, the Company will begin its operations in the development of bio-forensics and advanced genome and DNA technology under its newly developed Patmos Wellness program. This new exciting field offers a whole host of product lines that include technology platforms that allows for DNA sequencing and genome advancements to be put in place for the PATMOS Communities throughout the world.

This development will be lead by leading bio-technology scientist, Dr. Stephen T. Chen, PhD. from Princeton, New Jersey, USA. Dr. Chen currently serves on the board of various multinational public listed and private bio-technology research and development companies around the world. One of his core expertise is the advanced "drug delivery" system where different types of medicines and drugs can be administered in the most effective manner. He is currently involved in pioneering the scientifically developed Patmos Global Wellness Technologies for delivering advanced 21st Century Health Care Systems.

The GICE Sixth Sense™ "genome active" technology allows screening a person for cancers, HIV, H5n1, common colds, drug in-compatibilities, major health conditions and other serious ailments well in advance allowing for an alternative treatment and preventive method. The GICE Sixth Sense™ will be an important Preventive Wellness Technology that will initially be introduced throughout the PATMOS Platform™.

Dr. Chen was appointed today as the CEO and Chief Scientist of GICE Life Sciences Limited. He will lead a team of prominent DNA & GENOME technologist, experts and scientists in bringing this new "Life Sciences" to the PATMOS Platform™ on a global basis. An advanced bio-technology laboratory and testing facility will be setup within the PATMOS Platform™ to enable its Covenant Partners and its communities to experience a new frontier in Advanced Preventive Wellness Technologies™.

###